Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors
- Authors
- Kim, YY[Kim, Yeun-Yoon]; Lee, J[Lee, Jeeyun]; Jeong, WK[Jeong, Woo Kyoung]; Kim, ST[Kim, Seung Tae]; Kim, JH[Kim, Jae-Hun]; Hong, JY[Hong, Jung Yong]; Kang, WK[Kang, Won Ki]; Kim, KM[Kim, Kyoung-Mee]; Sohn, I[Sohn, Insuk]; Choi, D[Choi, Dongil]
- Issue Date
- Mar-2021
- Publisher
- SPRINGER
- Keywords
- Gastric cancer; Pembrolizumab; Nivolumab; Sarcopenia
- Citation
- GASTRIC CANCER, v.24, no.2, pp.457 - 466
- Indexed
- SCIE
SCOPUS
- Journal Title
- GASTRIC CANCER
- Volume
- 24
- Number
- 2
- Start Page
- 457
- End Page
- 466
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/7160
- DOI
- 10.1007/s10120-020-01124-x
- ISSN
- 1436-3291
- Abstract
- Background Sarcopenia has been underscored as a significant predictor of poor prognosis in cancer patients undergoing immunotherapy with programmed death-1 (PD-1) inhibitors. We aimed to investigate the prognostic significance of computed tomography (CT)-determined sarcopenia in patients with microsatellite-stable (MSS) gastric cancer (GC) treated with PD-1 inhibitors. Methods We retrospectively assessed patients with MSS GC who had been treated with PD-1 inhibitors from March 2016 to June 2019. Pre-treatment sarcopenic status was determined by analyzing L3 skeletal muscle index with abdominal CT. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan-Meier method, and the differences in survival probability according to sarcopenic status were compared using the log-rank test. Cox proportional hazards regression analyses were performed to identify predictors of PFS and OS. Results Of 149 patients with MSS GC (mean age, 57.0 +/- 12.3 years; 93 men), 79 (53.0%) had sarcopenia. Patients with sarcopenia had significantly shorter PFS than patients without sarcopenia (median, 1.4 months vs. 2.6 months;P = 0.026). Sarcopenia was independently associated with shorter PFS (adjusted hazard ratio [HR], 1.79; 95% confidence interval [CI], 1.10-2.93;P = 0.020). Patients with sarcopenia had shorter OS than patients without sarcopenia (median, 3.6 months vs. 4.9 months;P = 0.052), but sarcopenia itself was not a significant prognostic factor for OS (adjusted HR, 1.01; 95% CI, 0.58-1.75;P = 0.974). Conclusions CT-determined sarcopenia is an independent prognostic factor for PFS in patients with MSS GC treated with PD-1 inhibitors.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/7160)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.